Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it over to a new center in Harvard’s Enterprise Research Campus. | Roche and ...

The study by Ma et al. provides fundamental findings and compelling evidence that Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A ...

This study provides valuable insights into the efficacy and safety of pyrotinib as an extended adjuvant therapy following trastuzumab-based treatment in patients with high-risk HER2-positive breast ...

1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Search for other works by this author on: 1Department of Investigational Cancer ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung cancer (NSCLC), typically in female individuals, who are non-smokers, and have ...

"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically unfavourable mutation," according to Wolfgang Brueckl, MD, of t ...

Two of these newly launched products — Simlandi®, referencing Humira® (adalimumab), and Hercessi™, referencing Herceptin® (trastuzumab) — were latecomers entering crowded “first wave ...

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method that pulls apart the DNA molecule and amplifies the signal of each ...

Bangalore-based Biocon was expected to start selling a biosimilar version of Roche's blockbuster biologic drug Herceptin - which earned $6.4bn in global revenues for the Swiss company in 2012 - in ...